Cardiff Oncology (CRDF)

The company’s lead drug candidate is onvansertib, an oral and selective PLK1 inhibitor. Cardiff is evaluating onvansertib in treatment settings where patients have limited options and where tumor biology may make PLK1 inhibition especially relevant. Its main clinical focus includes RAS-mutated metastatic colorectal cancer, a large oncology market in which resistance to therapy remains a major challenge. The company also supports or participates in programs exploring the drug in other difficult-to-treat cancers.

Cardiff’s pipeline includes studies or investigator-initiated work in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple-negative breast cancer, and chronic myelomonocytic leukemia. Across these programs, the company generally seeks to combine onvansertib with standard therapies rather than replace them, aiming to improve response by targeting cancer-cell proliferation and survival mechanisms.

As a development-stage biotech, Cardiff does not operate like a commercial pharmaceutical company with diversified product revenue. Its valuation and risk profile are tied closely to clinical trial execution, regulatory feedback, safety and efficacy data, financing needs, and the potential for partnerships. The company operates from the United States and is positioned for investors who follow oncology drug development, precision medicine, and targeted therapy approaches in cancers with high unmet medical need.